A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)

The University of Virginia seeks adults ages 18 and over with ER+/HER2- Breast Cancer for a research study. You will be eligible if you have Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer with disease progression after prior endocrine based treatment.

You may be eligible for this study if:
- You have confirmed diagnosis of ER+/HER2- breast cancer
- Have had prior therapies for locoregional recurrent or metastatic disease
- One line of CDK4/6 inhibitor therapy in combination with endocrine therapy

Study involves blood draws, Electrocardiogram (ECG), tumor tissue biopsy, bone scans, and Computed Tomography (CT) scans.

There are 2 arms (or groups) of this study, you will be randomized (assigned by chance) into one of the two arms. The study drugs for each arm are as follows:
Arm A: ARV-471, once daily taken by mouth
Arm B: Fulvestrant, intramuscularly on Days 1 and 15 of Cycle 1 and on Day 1 of each cycle starting on Cycle 2 Day 1
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.

Additional information can be found here: Study Details | A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. | ClinicalTrials.gov

uvacancertrials@hscmail.mcc.virginia.edu